Envisia's ENV515 matches Travatan Z in glaucoma study

Envisia Therapeutics Inc. (Research Triangle Park, N.C.) said ENV515 met the primary endpoint in a Phase IIa trial to treat glaucoma. The extended-release formulation of travoprost significantly reduced intraocular pressure (IOP) in the dose-ranging study, and was comparable to Travatan Z travoprost from Novartis AG (NYSE:NVS; SIX:NOVN).

The 21-patient study identified a dose group in which a single dose of ENV515 reduced baseline IOP by 28% at day 25 (p<0.001), which was comparable to daily doses of Travatan Z. Envisia spokesperson Michael Parks told BioCentury that all four ENV515 doses evaluated in the study produced a significant reduction in IOP, with the highest dose producing changes comparable to Travatan Z. ...